Global Epilepsy Drugs
Market Report
2024
Epilepsy Drugs Market Report 2024 (Global Edition)
Delivery Includes:- Market Timeline 2019 till 2031, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
| Share your contact details to receive free updated sample copy/pages of the recently published edition of Epilepsy Drugs Market Report 2024.
Global Epilepsy Drugs Market Report 2024 Market Size Split by Type (First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics), by By Seizures Type (Non-epi...
According to cognitive market research, the global epilepsy drugs market size was valued at USD xx billion in 2024 and is expected to reach USD xx billion at a CAGR of xx% during the forecast period.
- Epilepsy is a common neurological disorder affecting people of all ages. As the global population continues to grow and age, the prevalence of epilepsy is expected to rise, which drives the market.
- The anti-epilepsy drugs reduce the excitability of brain nerve cells, which has an impact on regular function.
- The market prognosis for epileptic drugs is being positively impacted by the growing public knowledge of epilepsy and the range of treatment choices available for it, as well as by the government authorities' strategic alliance.
- Recent developments in epilepsy medication are evidenced by the creation and approval of novel antiepileptic medications (AEDs).
- North America dominated the market with the largest revenue share of around xx% in 2024. The region's high rate of epilepsy prevalence, which affects a sizable population, is a key element propelling the market for epilepsy medications.
| Base Year | 2023 |
| Historical Data Time Period | 2019-2023 |
| Forecast Period | 2024-2031 |
| Global Market Size | 121212 |
| Country Market Size | 121212 |
| North Americ Market Size | 121212 |
| Europe Market Size | 121212 |
| Asia Pacific Market Size | 121212 |
| South America Market Size | 121212 |
| Middle East and Africa Market Size | 121212 |
Market Drivers:
| |
Market Restrains:
| |
Market Trends:
| |
| Market Split by Type |
|
| Market Split by By Seizures Type |
|
| Market Split by By Distribution Channel |
|
| List of Competitors |
|
| Regional Analysis |
|
Country Analysis |
|
Key Qualitative Information Covered |
|
Report scope is customizable as we have a huge database of Epilepsy Drugs industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Epilepsy Drugs Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Epilepsy Drugs Market Report Description
Introduction of the Epilepsy Drugs Market
Epilepsy is a common neurological disorder affecting people of all ages. As the global population continues to grow and age, the prevalence of epilepsy is expected to rise, which drives the market.
Although the precise etiology of epilepsy is sometimes unclear, several variables, including genetics, brain trauma, infections, and prenatal conditions, have been linked to the condition. There are three types of seizures associated with epilepsy: focal, generalized, and non-epileptic. Antiepileptic drugs are typically used to treat epilepsy because they assist in regulating seizures.
Market Dynamics of the Epilepsy Drugs Market
Key Drivers of the Epilepsy Drugs Market
- The increasing prevalence of epilepsy worldwide significantly boosts the market for epilepsy drugs
Recurrent seizures are the hallmark of epilepsy, a neurological illness that is affecting an increasing number of individuals worldwide. Several causes, such as an aging population and advancements in diagnostic methods that allow for more precise identification of epileptic patients, are responsible for this increase in prevalence. Compared to high-income countries, the incidence of childhood epilepsy is three times greater in low- and middle-income nations. Serious neurological conditions like epilepsy are linked to stigma and prejudice, lower quality of life, and other issues with mental health. The need for efficient and widely available therapies for epilepsy is growing along with the number of persons receiving epilepsy diagnoses. Epilepsy is becoming more and more prevalent in both prevalence and incidence, especially in low- and middle-income nations.
• For instance, The World Health Organization (WHO) has published in its 2023 report, the WHO estimated that there are over 50 million people with epilepsy globally. The reports also estimated that the proportion of the general population with active epilepsy at a given time is between 4 and 10 per 1000 people.
(Source:https://www.who.int/news-room/fact-sheets/detail/epilepsy)
- Governments Providing funds for the treatment of epilepsy is a driver for the market
Government activities that focus on increasing awareness, better diagnosis, and improving treatment choices for people affected are vital in driving the market for epilepsy drugs. These programs include a range of activities aimed at raising awareness about epilepsy and its management, including community outreach programs, public education campaigns, and training programs for healthcare providers. Governments also provide funding for epilepsy research and development, assisting researchers and pharmaceutical firms in developing novel therapies and refining those that already exist. The money makes it possible to create safer and more effective epilepsy medicines.
• For instance, The UK government's statement on March 7 mentioned that $48.92 million would support the initiation of careers for upcoming medical researchers focusing on epilepsy treatment.
(Source:https://www.epilepsy.org.uk/spring-budget-2024-funding-for-epilepsy-research-announced)
Restraints of the Epilepsy Drugs Market
- The side effects associated with epilepsy drugs may hamper the market growth of the epilepsy drugs
Common adverse effects of epilepsy medications include cognitive impacts such as mood swings, gastrointestinal distress, memory problems, and dizziness. In certain situations, anti-epilepsy medications might alter how the brain functions. These anti-epilepsy drugs reduce the excitability of brain nerve cells, which has an impact on regular function. Changes in weight and skin responses are also likely. Many people may decide to stop taking their medication as a result of these adverse effects, which can negatively affect everyday functioning and quality of life. Thus, the adverse effects of epilepsy medications may prevent their widespread use, which would restrict the market's expansion.
• For instance, regarding two commonly used medications for epilepsy, levetiracetam, and clobazam, the FDA issued a caution. The medications appear to be connected to Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome, an uncommon but dangerous allergic reaction. Worldwide, reports of over 40 cases of DRESS syndrome a potentially fatal reaction in patients taking these medications have been made.
(Source:https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-rare-serious-drug-reaction-antiseizure-medicines-levetiracetam-keppra-keppra-xr-elepsia-xr)
How Did Covid-19 Impact the Epilepsy Drugs Market
The COVID-19 pandemic severely hindered the expansion of the neurology market by interfering with many neurology-related activities, including medical research and teaching. The COVID-19 pandemic-related lockdown that was implemented in several nations has caused economic division and hindered the private healthcare industry's ability to operate. In the first phase of the market's expansion, COVID-19 had a major influence. But because the products have been approved, it is expected that the market will grow in the upcoming years. Patients with epilepsy experienced increased seizure frequency, despair, anxiety, unemployment, and financial hardship in accessing medicine due to the present COVID-19 epidemic.
• For instance, 30.3% of patients had reported increased seizure frequency during the COVID-19 pandemic, which could also be due to patients missing their regular medication, sleep deprivation, or due to shortages of supply of medication because of the nationwide lockdown.
(Source:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061515/)
Opportunities of the Epilepsy Drugs Market
- Increasing research and development infrastructure is an opportunity for the market
Recent developments in epilepsy medication are evidenced by the creation and approval of novel antiepileptic medications (AEDs). A study to enhance the treatment of patients with epilepsy and decrease needless A&E admissions has been spearheaded by academics at the University of Liverpool. By increasing therapy alternatives, reducing side effects, and enhancing efficacy, these improvements improve treatment results. These developments demonstrate encouraging advances in the research and development of epileptic drugs and will support the future expansion and growth of the global epilepsy medicine industry.
• For instance, in November 2023 The EpiSafe project, funded by the National Institute for Health and Care Research over five years, announced its plan to create an evidence-based, personalized care bundle specifically designed for pregnant women with epilepsy.
(Source:https://www.birmingham.ac.uk/news/2023/epilepsy-and-pregnancy-new-project-to-create-personalised-care-for-at-risk-mums-1)
• For instance, in October 2022, Avicanna Inc. expanded its research collaboration in epilepsy with a new collaboration with the University of Toronto. It is to explore the efficacy of Avicanna's proprietary formulations in pre-clinical models for epilepsy.
(Source:https://www.bioworld.com/articles/689730-avicanna-collaborates-with-university-of-toronto-to-advance-epilepsy-research?v=preview)
We have various report editions of Epilepsy Drugs Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Competitive Landscape: Epilepsy Drugs Market
There are several firms in the epilepsy medicine industry producing medications to help control seizures. These medications come in various forms, such as tablets and liquids, and function in various ways. These medications are also available in generic form, which is frequently less expensive. These businesses are always working to develop more potent medications with fewer adverse effects. For these businesses to compete in the market, obtaining regulatory permission, expanding their patient base, determining pricing, and collaborating with healthcare professionals are all crucial.
Top Companies Market Share in Epilepsy Drugs Industry: (In no particular order of Rank)
- Abbott Laboratories
- GlaxoSmithKline Plc
- UCB
- Cephalon
- Johnson & Johnson
- Pfizer
- Novartis AG
- Abbvie
- Janssen Pharmaceuticals
- Sunovion Pharmaceuticals
- Bausch Health
- Sanofi S.A
- Takeda
- Eisai
- F. Hoffmann La Roche
- Confidential Data
- Access The Paid Version
- Data Hidden
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
Which region dominates the epilepsy drugs market?
North America dominated the market with the largest revenue share of around xx% in 2024. The region's high rate of epilepsy prevalence, which affects a sizable population, is a key element propelling the market for epilepsy medications. In the United States, 3 million people and 470,000 children have been diagnosed with epilepsy, according to the CDC. Another important element propelling the market in the area is the growing awareness of the illness and its symptoms. The rising awareness regarding epilepsy and its available treatment options, along with the strategic alliance of government authorities, is positively impacting the epilepsy drug market outlook. The market prognosis for epileptic drugs is being positively impacted by the growing public knowledge of epilepsy and the range of treatment choices available for it, as well as by the government authorities' strategic alliance.
Which region expanding at the fastest CAGR in the epilepsy drugs market?
Asia Pacific is estimated to expand at the highest CAGR of xx% over the forecast period. The introduction of new-generation anti-epileptic medications and the existence of supportive government programs like the Intersectoral Global Action Plan on Epilepsy, Global Campaign Against Epilepsy, and others are anticipated to fuel the market's expansion in the area. The presence of significant unmet medical requirements in the developing economies of China and India, as well as growing patient knowledge of efficient medications for epilepsy, are other factors driving the expansion of the regional market. Furthermore, China's drug regulatory body authorized a necessary medicine in September 2022 for the treatment of pediatric epilepsy. In October 2022, the drug's native manufacturer publicly released it into the market, claiming that its pricing was the most competitive globally. Generic Clobazam will be available for purchase in neighborhood pharmacies across the country for 84 yuan (USD 12) per package of 28 pills. Consequently, these factors aid in the growth of the local market.
The current report Scope analyzes Epilepsy Drugs Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
- Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
Epilepsy Drugs Market Share (%) by Region (2019-2031)
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
Epilepsy Drugs Market Analysis
Global Epilepsy Drugs Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Epilepsy Drugs Industry growth. Epilepsy Drugs market has been segmented with the help of its Type, By Seizures Type, and others. Epilepsy Drugs market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
Epilepsy Drug Market Treatment Type Analysis
- First Generation
- Second Generation
- Third Generation
Based on the treatment the market is segmented into first generation, second generation, and third generation anti-epileptics. The third-generation segment accounted for the largest revenue share of around xx% in 2024. Third-generation anti-epileptic pharmaceuticals function differently from first- and second-generation anti-epileptic drugs in several ways, such as by blocking excitatory amino acid receptors, inhibiting the release of neurotransmitters, and using innovative techniques to inactivate sodium channels. New mechanisms of action in the third generation of anticonvulsants boost the likelihood of treating epileptic products refractory to previous anticonvulsants. One major benefit of third-generation anti-epileptics is that their limited potential to interact with other drugs, including other anti-epileptics, makes prescribing them for neurologists much easier and safer. The increasing prevalence of epilepsy and improvements in third-generation anti-epileptic approaches are the main factors driving segment growth.
• For instance, in February 2021, Sun Pharmaceutical Industries Ltd. launched the third-generation anti-epileptic drug Brivaracetam in several dosage forms, including 25 mg, 50 mg, 75 mg, and 100 mg, at an affordable price.
(Source:https://sunpharma.com/wp-content/uploads/2021/02/Press-Release-Sun-Pharma-to-introduce-Brivaracetam-at-an-affordable-price-in-India.pdf)
Epilepsy Drugs Market Share (%) by Type in 2019-2031
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Epilepsy Drugs Industry. Request a Free Sample PDF!
Segment Analysis of Epilepsy Drugs Market
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities for each application of Epilepsy Drugs from 2019 to 2031. This will also help to analyze the demand for Epilepsy Drugs across different end-use industries. Our research team will also help acquire additional data such as Value Chain, Patent analysis, Company Evaluation Quadrant (Matrix), and much more confidential analysis and data insights.
Some of the key of Epilepsy Drugs are:
Epilepsy Drugs Market Share (%) by in 2019-2031
2019
2023
2031
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
Epilepsy Drugs By Seizures Type Segment Analysis
- Non-epileptic Seizures
- Generalized Seizures
- Focal Seizures
Epilepsy Drugs By Distribution Channel Segment Analysis
The drug stores and retail pharmacies held the largest market epilepsy drugs market share in 2024 and are expected to remain dominant throughout the forecast period, due to the distribution channel's capacity to provide quick and simple access to a large selection of medications, sufficient inventory, and the items' affordable retail prices. Nonetheless, during the course of the projection period, the internet providers category is anticipated to record the greatest CAGR. This is ascribed to the ease with which epilepsy medications are accessible and available as well as the growth in technical improvements for internet platforms.
• For instance, Pharmanovia purchased Frisium, an epilepsy medication, from Sanofi. Clobazam, marketed under the name Frisium, is an adjuvant medication used in conjunction with other medications for epilepsy. It is a benzodiazepine, and its mechanism of action is to slow down the brain and body's processes. Global healthcare provider Pharmanovia is based in Basildon, Essex. Pharmanovia went on to say that the packaging will probably be the only alteration made to Frisium's branding.
(Source:https://pharmanovia.com/news/pharmanovia-acquires-global-central-nervous-system-cns-portfolio-from-sanofi/)
- Hospital Pharmacies
- Drug store & Retail Pharmacies
- Online Pharmacies
Author's Detail
Manjiri KanhereSenior Research Associate at Cognitive Market Research
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over three years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies.
In her current role, Manjiri handles the market research related to Pharma and healthcare industry. Her passion lies in utilizing innovative approaches to distill complex information into strategic insights that empower organizations to make informed decisions.Manjiri remains an invaluable asset in the dynamic landscape of market research.
Author's Conclusion
Epilepsy is a common neurological disorder affecting people of all ages. As the global population continues to grow and age, the prevalence of epilepsy is expected to rise, which drives the market. These businesses are always working to develop more potent medications with fewer adverse effects. Governments also provide funding for epilepsy research and development, assisting researchers and pharmaceutical firms in developing novel therapies and refining those that already exist. The money makes it possible to create safer and more effective epilepsy medicines.
Frequently Asked Questions
Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.
Latest News about Epilepsy Drugs Market
• In July 2023: Viatris Inc., a worldwide medical organization, and Kindeva Drug Delivery L.P. announced the launch of Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the primary conventional variant of AstraZeneca Symbicort with an Abbreviated New Drug Application (ANDA) approved by the U.S. Food and Drug Administration (FDA).
(Source:https://newsroom.viatris.com/2023-07-31-Viatris-Announces-Launch-of-Breyna-TM-budesonide-and-formoterol-fumarate-dihydrate-Inhalation-Aerosol,-the-First-FDA-Approved-Generic-Version-of-Symbicort-R-for-People-with-Asthma-and-Chronic-Obstructive-Pulmonary-Disease,-in-Partnership-with-K )
• In August 2023, The U.S. Food and Drug Administration (FDA) approved ZURZUVAE 50 mg for individuals with postpartum depression (PPD), according to a statement from Biogen Inc. and Sage Therapeutics, Inc. For women with PPD, ZURZUVAE is the first and sole oral, once-daily, 14-day medication that can significantly reduce depression symptoms.
(Source:https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-treatment-postpartum-depression )
• April 2022- pharmaceutical firm Lundbeck's antidepressant vortioxetine, sold under brand names Trintellix and Brintellix, demonstrated an advantage in a head-to-head study against desvenlafaxine, which Pfizer is marketing in the United States as Pristiq. The study investigated the efficacy of vortioxetine in patients with Major Depressive Disorder (MDD) who had a partial response to selective serotonin reuptake inhibitor (SSRI) treatment compared to desvenlafaxine.
(Source:https://medwatch.com/News/Pharma___Biotech/article13914099.ece )
• For instance, in December 2021, Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on developing and commercializing therapeutics for central nervous system (CNS) disorders, received approval from the FDA for CAPLYTA (lumateperone) for the treatment of bipolar depression in adults.
(Source:https://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-announces-us-fda-approval-caplytar )
Sources from Pharma & Healthcare Industry
- https://en.wikipedia.org/wiki/American_Society_for_Pharmacy_Law
- https://en.wikipedia.org/wiki/American_Society_of_Consultant_Pharmacists
- https://en.wikipedia.org/wiki/American_Society_of_Health-System_Pharmacists
- https://www.apsm-uk.com/
- https://en.wikipedia.org/wiki/Australasian_College_of_Pharmacy
- https://en.wikipedia.org/wiki/American_Association_of_Colleges_of_Pharmacy
- https://en.wikipedia.org/wiki/American_College_of_Clinical_Pharmacy
- https://en.wikipedia.org/wiki/American_Pharmacists_Association
- https://www.bio.org/
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Association
- https://en.wikipedia.org/wiki/Canadian_Society_of_Hospital_Pharmacists
- https://en.wikipedia.org/wiki/Chinese_Pharmaceutical_Association
- https://en.wikipedia.org/wiki/American_Association_of_Psychiatric_Pharmacists
- https://en.wikipedia.org/wiki/Danish_Association_of_Pharmaconomists
- https://en.wikipedia.org/wiki/EPhEU
- https://www.fda.gov/
- https://www.gmc-uk.org/
- https://www.ifpma.org/
- https://www.fip.org/
- https://en.wikipedia.org/wiki/International_Pharmaceutical_Students%27_Federation
- https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
- https://en.wikipedia.org/wiki/National_Pharmacy_Association
- https://en.wikipedia.org/wiki/Norwegian_Pharmacy_Association
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Journal#History
- https://en.wikipedia.org/wiki/Pakistan_Pharmacists_Association
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Mauritius
- https://en.wikipedia.org/wiki/Pharmaceutical_Group_of_the_European_Union
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Australia
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_New_Zealand
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Northern_Ireland
- https://en.wikipedia.org/wiki/Professional_Compounding_Centers_of_America
- https://en.wikipedia.org/wiki/Royal_Pharmaceutical_Society
- https://www.aaps.org/home
- https://www.bioindustry.org/
- https://www.controlledreleasesociety.org/
- https://www.efpia.eu/
- https://www.epemed.org/online/www/content/ENG/index.html
- https://icr-global.org/
- https://ispe.org/
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Israel
- https://www.phrma.org/
- https://en.wikipedia.org/wiki/The_Pharmacy_Guild_of_Australia
- https://en.wikipedia.org/wiki/The_Society_of_Hospital_Pharmacists_of_Australia
- https://en.wikipedia.org/wiki/Healthcare_industry
- https://www.pharma-iq.com/business-development/articles/top-50-pharmaceutical-blogs-and-publications
- https://www.pharmatimes.com/news
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967517/
- https://www.cbo.gov/publication/57126
- http://: https://www.who.int/tools/atc-ddd-toolkit/data
- https://www.oecd.org/els/health-systems/health-data.htm
- https://www.bls.gov/ooh/healthcare/home.htm
- https://data.worldbank.org/topic/8
- https://www.statnews.com/about/
- https://www.health.pa.gov/topics/HealthStatistics/Pages/health-statistics.aspx
- https://www.cdc.gov/nchs/index.htm
- https://www.aha.org/statistics/fast-facts-us-hospitals
- https://www.census.gov/library/publications/2021/demo/p60-274.html
- https://www.adb.org/what-we-do/sectors/health/main
Epilepsy Drugs Market Report Table of Content
Disclaimer:
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
| Type | First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics |
| By Seizures Type | Non-epileptic Seizures, Generalized Seizures, Focal Seizures |
| By Distribution Channel | Hospital Pharmacies, Drug store & Retail Pharmacies, Online Pharmacies |
| List of Competitors | Abbott Laboratories, GlaxoSmithKline Plc, UCB, Cephalon, Johnson & Johnson, Pfizer, Novartis AG, Abbvie, Janssen Pharmaceuticals, Sunovion Pharmaceuticals, Bausch Health, Sanofi S.A, Takeda, Eisai, F. Hoffmann La Roche |
This chapter will help you gain GLOBAL Market Analysis of Epilepsy Drugs. Further deep in this chapter, you will be able to review Global Epilepsy Drugs Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
-
1.1 Global Epilepsy Drugs Market Size, Trend Analysis 2019 - 2031
-
1.2 Global Epilepsy Drugs Market Size By Regions 2019 - 2031
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
-
1.2.1 Global Epilepsy Drugs Revenue Market Size By Region
-
-
1.3 Global Epilepsy Drugs Market Size By Type 2019 -2031
-
1.3.1 First Generation Anti-epileptics Market Size
-
1.3.2 Second Generation Anti-epileptics Market Size
-
1.3.3 Third Generation Anti-epileptics Market Size
-
-
1.4 Global Epilepsy Drugs Market Size By By Seizures Type 2019 -2031
-
1.4.1 Non-epileptic Seizures Market Size
-
1.4.2 Generalized Seizures Market Size
-
1.4.3 Focal Seizures Market Size
-
-
1.5 Global Epilepsy Drugs Market Size By By Distribution Channel for 2019 -2031
-
1.5.1 Hospital Pharmacies Market Size
-
1.5.2 Drug store & Retail Pharmacies Market Size
-
1.5.3 Online Pharmacies Market Size
-
-
1.6 Global Level Competitor Analysis (Subject to Data Availability (Private Players))
-
1.7 Executive Summary Global Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
-
1.7.1 Regional Market Revenue Summary 2019 vs 2024 vs 2031
-
1.7.2 Global Market Revenue Split By Type
-
1.7.3 Global Market Revenue Split By By Seizures Type
-
1.7.4 Global Market Revenue Split By By Distribution Channel
-
1.7.5 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
-
Chapter 2 North America Market Analysis
-
2.1 North America Epilepsy Drugs Market Size 2019 - 2031
-
2.1.1 North America Epilepsy Drugs Market Size By Country 2019 - 2031
-
2.1.2 North America Epilepsy Drugs Market Size by Type 2019 -2031
-
2.1.2.1 North America First Generation Anti-epileptics Market Size
-
2.1.2.2 North America Second Generation Anti-epileptics Market Size
-
2.1.2.3 North America Third Generation Anti-epileptics Market Size
-
-
2.1.3 North America Epilepsy Drugs Market Size by By Seizures Type 2019 -2031
-
2.1.3.1 North America Non-epileptic Seizures Market Size
-
2.1.3.2 North America Generalized Seizures Market Size
-
2.1.3.3 North America Focal Seizures Market Size
-
-
2.1.4 North America Epilepsy Drugs Market Size by By Distribution Channel 2019 -2031
-
2.1.4.1 North America Hospital Pharmacies Market Size
-
2.1.4.2 North America Drug store & Retail Pharmacies Market Size
-
2.1.4.3 North America Online Pharmacies Market Size
-
-
Chapter 3 Europe Market Analysis
-
3.1 Europe Epilepsy Drugs Market Size 2019 - 2031
-
3.1.1 Europe Epilepsy Drugs Market Size By Country 2019 - 2031
-
3.1.2 Europe Epilepsy Drugs Market Size by Type 2019 -2031
-
3.1.2.1 Europe First Generation Anti-epileptics Market Size
-
3.1.2.2 Europe Second Generation Anti-epileptics Market Size
-
3.1.2.3 Europe Third Generation Anti-epileptics Market Size
-
-
3.1.3 Europe Epilepsy Drugs Market Size by By Seizures Type 2019 -2031
-
3.1.3.1 Europe Non-epileptic Seizures Market Size
-
3.1.3.2 Europe Generalized Seizures Market Size
-
3.1.3.3 Europe Focal Seizures Market Size
-
-
3.1.4 Europe Epilepsy Drugs Market Size by By Distribution Channel 2019 -2031
-
3.1.4.1 Europe Hospital Pharmacies Market Size
-
3.1.4.2 Europe Drug store & Retail Pharmacies Market Size
-
3.1.4.3 Europe Online Pharmacies Market Size
-
-
Chapter 4 Asia Pacific Market Analysis
-
4.1 Asia Pacific Epilepsy Drugs Market Size 2019 - 2031
-
4.1.1 Asia Pacific Epilepsy Drugs Market Size By Country 2019 - 2031
-
4.1.2 Asia Pacific Epilepsy Drugs Market Size by Type 2019 -2031
-
4.1.2.1 Asia Pacific First Generation Anti-epileptics Market Size
-
4.1.2.2 Asia Pacific Second Generation Anti-epileptics Market Size
-
4.1.2.3 Asia Pacific Third Generation Anti-epileptics Market Size
-
-
4.1.3 Asia Pacific Epilepsy Drugs Market Size by By Seizures Type 2019 -2031
-
4.1.3.1 Asia Pacific Non-epileptic Seizures Market Size
-
4.1.3.2 Asia Pacific Generalized Seizures Market Size
-
4.1.3.3 Asia Pacific Focal Seizures Market Size
-
-
4.1.4 Asia Pacific Epilepsy Drugs Market Size by By Distribution Channel 2019 -2031
-
4.1.4.1 Asia Pacific Hospital Pharmacies Market Size
-
4.1.4.2 Asia Pacific Drug store & Retail Pharmacies Market Size
-
4.1.4.3 Asia Pacific Online Pharmacies Market Size
-
-
Chapter 5 South America Market Analysis
-
5.1 South America Epilepsy Drugs Market Size 2019 - 2031
-
5.1.1 South America Epilepsy Drugs Market Size By Country 2019 - 2031
-
5.1.2 South America Epilepsy Drugs Market Size by Type 2019 -2031
-
5.1.2.1 South America First Generation Anti-epileptics Market Size
-
5.1.2.2 South America Second Generation Anti-epileptics Market Size
-
5.1.2.3 South America Third Generation Anti-epileptics Market Size
-
-
5.1.3 South America Epilepsy Drugs Market Size by By Seizures Type 2019 -2031
-
5.1.3.1 South America Non-epileptic Seizures Market Size
-
5.1.3.2 South America Generalized Seizures Market Size
-
5.1.3.3 South America Focal Seizures Market Size
-
-
5.1.4 South America Epilepsy Drugs Market Size by By Distribution Channel 2019 -2031
-
5.1.4.1 South America Hospital Pharmacies Market Size
-
5.1.4.2 South America Drug store & Retail Pharmacies Market Size
-
5.1.4.3 South America Online Pharmacies Market Size
-
-
Chapter 6 Middle East and Africa Market Analysis
-
6.1 Middle East and Africa Epilepsy Drugs Market Size 2019 - 2031
-
6.1.1 Middle East and Africa Epilepsy Drugs Market Size By Country 2019 - 2031
-
6.1.2 Middle East and Africa Epilepsy Drugs Market Size by Type 2019 -2031
-
6.1.2.1 Middle East and Africa First Generation Anti-epileptics Market Size
-
6.1.2.2 Middle East and Africa Second Generation Anti-epileptics Market Size
-
6.1.2.3 Middle East and Africa Third Generation Anti-epileptics Market Size
-
-
6.1.3 Middle East and Africa Epilepsy Drugs Market Size by By Seizures Type 2019 -2031
-
6.1.3.1 Middle East and Africa Non-epileptic Seizures Market Size
-
6.1.3.2 Middle East and Africa Generalized Seizures Market Size
-
6.1.3.3 Middle East and Africa Focal Seizures Market Size
-
-
6.1.4 Middle East and Africa Epilepsy Drugs Market Size by By Distribution Channel 2019 -2031
-
6.1.4.1 Middle East and Africa Hospital Pharmacies Market Size
-
6.1.4.2 Middle East and Africa Drug store & Retail Pharmacies Market Size
-
6.1.4.3 Middle East and Africa Online Pharmacies Market Size
-
-
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis (Only Available with Corporate User License)
-
7.1 Country 1 Market Analysis
-
7.1.1 Country 1Epilepsy Drugs Market Size by Type 2019 -2031
-
7.1.2 Country 1Epilepsy Drugs Market Size by By Seizures Type 2019 -2031
-
7.1.3 Country 1Epilepsy Drugs Market Size by By Distribution Channel 2019 -2031
-
-
7.2 Country 2 Market Analysis
-
7.2.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.3 Country 3 Market Analysis
-
7.3.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.4 Country 4 Market Analysis
-
7.4.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.5 Country 5 Market Analysis
-
7.5.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.6 Country 6 Market Analysis
-
7.6.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.7 Country 7 Market Analysis
-
7.7.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.8 Country 8 Market Analysis
-
7.8.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.9 Country 9 Market Analysis
-
7.9.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.10 Country 10 Market Analysis
-
7.10.1 Segmentation Analysis will be provided as shown for Country 1
-
Competitor's Market Share and Revenue (Subject to Data Availability for Private Players)
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
-
8.1 Top Competitors Analysis
-
8.1.1 Top Players Ranking 2022
-
8.1.2 Global Epilepsy Drugs Market Revenue and Share by Manufacturers (2019-2023)
(Subject to Data Availability (Private Players))
-
8.1.3 Industry Mergers and Acquisition Analysis
-
8.1.4 New Product Launch Analysis
-
-
8.2 Company Profile (Data Subject to Availability)
-
8.2.1 Abbott Laboratories
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.1.2 Business Overview
-
8.2.1.3 Financials (Subject to data availability)
-
8.2.1.4 Product Types Specification
-
8.2.1.5 Business Strategy
-
8.2.1.6 S.W.O.TAnalysis
-
-
8.2.2 GlaxoSmithKline Plc
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.2.2 Business Overview
-
8.2.2.3 Financials (Subject to data availability)
-
8.2.2.4 Product Types Specification
-
8.2.2.5 Business Strategy
-
8.2.2.6 S.W.O.TAnalysis
-
-
8.2.3 UCB
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.3.2 Business Overview
-
8.2.3.3 Financials (Subject to data availability)
-
8.2.3.4 Product Types Specification
-
8.2.3.5 Business Strategy
-
8.2.3.6 S.W.O.TAnalysis
-
-
8.2.4 Cephalon
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.4.2 Business Overview
-
8.2.4.3 Financials (Subject to data availability)
-
8.2.4.4 Product Types Specification
-
8.2.4.5 Business Strategy
-
8.2.4.6 S.W.O.TAnalysis
-
-
8.2.5 Johnson & Johnson
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.5.2 Business Overview
-
8.2.5.3 Financials (Subject to data availability)
-
8.2.5.4 Product Types Specification
-
8.2.5.5 Business Strategy
-
8.2.5.6 S.W.O.TAnalysis
-
-
8.2.6 Pfizer
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.6.2 Business Overview
-
8.2.6.3 Financials (Subject to data availability)
-
8.2.6.4 Product Types Specification
-
8.2.6.5 Business Strategy
-
8.2.6.6 S.W.O.TAnalysis
-
-
8.2.7 Novartis AG
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.7.2 Business Overview
-
8.2.7.3 Financials (Subject to data availability)
-
8.2.7.4 Product Types Specification
-
8.2.7.5 Business Strategy
-
8.2.7.6 S.W.O.TAnalysis
-
-
8.2.8 Abbvie
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.8.2 Business Overview
-
8.2.8.3 Financials (Subject to data availability)
-
8.2.8.4 Product Types Specification
-
8.2.8.5 Business Strategy
-
8.2.8.6 S.W.O.TAnalysis
-
-
8.2.9 Janssen Pharmaceuticals
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.9.2 Business Overview
-
8.2.9.3 Financials (Subject to data availability)
-
8.2.9.4 Product Types Specification
-
8.2.9.5 Business Strategy
-
8.2.9.6 S.W.O.TAnalysis
-
-
8.2.10 Sunovion Pharmaceuticals
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.10.2 Business Overview
-
8.2.10.3 Financials (Subject to data availability)
-
8.2.10.4 Product Types Specification
-
8.2.10.5 Business Strategy
-
8.2.10.6 S.W.O.TAnalysis
-
-
8.2.11 Bausch Health
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.11.2 Business Overview
-
8.2.11.3 Financials (Subject to data availability)
-
8.2.11.4 Product Types Specification
-
8.2.11.5 Business Strategy
-
8.2.11.6 S.W.O.TAnalysis
-
-
8.2.12 Sanofi S.A
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.12.2 Business Overview
-
8.2.12.3 Financials (Subject to data availability)
-
8.2.12.4 Product Types Specification
-
8.2.12.5 Business Strategy
-
8.2.12.6 S.W.O.TAnalysis
-
-
8.2.13 Takeda
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.13.2 Business Overview
-
8.2.13.3 Financials (Subject to data availability)
-
8.2.13.4 Product Types Specification
-
8.2.13.5 Business Strategy
-
8.2.13.6 S.W.O.TAnalysis
-
-
8.2.14 Eisai
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.14.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.14.2 Business Overview
-
8.2.14.3 Financials (Subject to data availability)
-
8.2.14.4 Product Types Specification
-
8.2.14.5 Business Strategy
-
8.2.14.6 S.W.O.TAnalysis
-
-
8.2.15 F. Hoffmann La Roche
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.15.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.15.2 Business Overview
-
8.2.15.3 Financials (Subject to data availability)
-
8.2.15.4 Product Types Specification
-
8.2.15.5 Business Strategy
-
8.2.15.6 S.W.O.TAnalysis
-
-
Chapter 9 Qualitative Analysis (Subject to Data Availability)
-
9.1 Market Drivers
-
9.2 Market Trends
-
9.3 Market Restraints
-
9.4 Market Opportunity
-
9.5 Product Life Cycle (Subject to Data Availability)
-
9.6 Industrial Chain Analysis (Subject to Data Availability)
-
9.6.1 Industry Chain Analysis
-
9.6.2 Manufacturing Cost Analysis
-
9.6.3 Consumer Preference Analysis
-
9.6.4 Supply Side Analysis
-
9.6.4.1 Raw Material Analysis
-
9.6.4.2 Raw Material Procurement Analysis
-
9.6.4.3 Raw Material Price Trend Analysis
-
-
-
9.7 Market Attractiveness Analysis
-
9.8 PESTEL Analysis
-
9.9 Porter’s Five Forces Analysis
-
9.10 Patent Analysis (Subject to Data Availability)
-
9.11 ESG Analysis
-
9.12 Technological Road Map
Segmentation Type Analysis 2019 -2031, will provide market size split by Type. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Type Analysis 2019 -2031
-
10.1 First Generation Anti-epileptics
-
10.1.1 Global Epilepsy Drugs Revenue Market Size and Share by First Generation Anti-epileptics 2019 -2031
-
-
10.2 Second Generation Anti-epileptics
-
10.2.1 Global Epilepsy Drugs Revenue Market Size and Share by Second Generation Anti-epileptics 2019 -2031
-
-
10.3 Third Generation Anti-epileptics
-
10.3.1 Global Epilepsy Drugs Revenue Market Size and Share by Third Generation Anti-epileptics 2019 -2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by By Seizures Type Analysis 2019 -2031
-
11.1 Non-epileptic Seizures
-
11.1.1 Global Epilepsy Drugs Revenue Market Size and Share by Non-epileptic Seizures 2019 -2031
-
-
11.2 Generalized Seizures
-
11.2.1 Global Epilepsy Drugs Revenue Market Size and Share by Generalized Seizures 2019 -2031
-
-
11.3 Focal Seizures
-
11.3.1 Global Epilepsy Drugs Revenue Market Size and Share by Focal Seizures 2019 -2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by By Distribution Channel Analysis 2019 -2031
-
12.1 Hospital Pharmacies
-
12.1.1 Global Epilepsy Drugs Revenue Market Size and Share by Hospital Pharmacies 2019 -2031
-
-
12.2 Drug store & Retail Pharmacies
-
12.2.1 Global Epilepsy Drugs Revenue Market Size and Share by Drug store & Retail Pharmacies 2019 -2031
-
-
12.3 Online Pharmacies
-
12.3.1 Global Epilepsy Drugs Revenue Market Size and Share by Online Pharmacies 2019 -2031
-
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Epilepsy Drugs market
Chapter 13 Research Findings
-
13.1 Key Takeaways
-
13.2 Analyst Point of View
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
-
13.3 Assumptions and Acronyms
Sample Format of Deliverables
The Tables, Graphs/Charts are only for representative purposes and do not depict actual statistics. Purchase full Report access to actual data.
Qualitative Analysis
Research Methodology Implemented by Manjiri Kanhere and Team
- 1.1 Epilepsy Drugs Market Report 2024 Research Methodology
- 1.2 Systematic Research Approach
- 1.2.1 Primary Research for Epilepsy Drugs Market
- 1.2.1.1 Key Data from Primary
- 1.2.1.2 Primary Interviews with Experts
- 1.2.1.3 Key Industry Insights
- 1.2.1.4 Questionnaire for Epilepsy Drugs Market
- 1.2.1.5 Breakdown of Primaries
- 1.2.2 Secondary Research for Epilepsy Drugs Market
- 1.2.2.1 Key Data from Secondary
- 1.2.2.2 Paid Sources
- 1.2.2.3 Public Sources
- 1.3 Market Size Estimation for Epilepsy Drugs Market
- 1.3.1 Top-Down Approach
- 1.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
- 1.3.2 Bottom-UP Approach
- 1.3.2.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
- 1.3.1 Top-Down Approach
- 1.4 Market Breakdown and Data Triangulation
- 1.5 Research Assumptions for Epilepsy Drugs Market
Key Questions Answered By Epilepsy Drugs Market Report 2024
| Why First Generation Anti-epileptics have a significant impact on Epilepsy Drugs market? |
| What are the key factors affecting the First Generation Anti-epileptics and Second Generation Anti-epileptics of Epilepsy Drugs Market? |
| What is the CAGR/Growth Rate of during the forecast period? |
| By type, which segment accounted for largest share of the global Epilepsy Drugs Market? |
| Which region is expected to dominate the global Epilepsy Drugs Market within the forecast period? |
| Segmentation Level Customization |
|
| Global level Data Customization |
|
| Region level Data Customization |
|
| Country level Data Customization |
|
| Company Level |
|
| Additional Data Analysis |
|
| Additional Qualitative Data |
|
| Additional Quantitative Data |
|
| Service Level Customization |
|
Report Format Alteration |
|
